Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

responses observed in this trial represent a clinically meaningful outcome for many of these difficult-to-treat AML patients. As a single-agent, single-infusion therapy, Cloretazine(R) (VNP40101M) has the potential to be an important new treatment option for older patients with poor-risk AML."

Alan Kessman, Chief Executive Officer, said, "These interim data continue to demonstrate Cloretazine(R) (VNP40101M)'s potential utility in a patient population which represents an unmet medical need." He added, "It continues to be our plan to file a new drug application with the U.S. Food and Drug Administration in 2008 based on the data from this trial and our previous Phase II trial in elderly patients with AML."

The pivotal Phase II trial started in May 2006 and was conducted in 25 sites in North America and Europe. Enrollment of the primary study was completed in August 2007. The trial remains open at selected sites in order to collect QT/QTc interval data in an electrocardiogram sub-study in accordance with FDA/ICH guidelines.

The study was designed for patients with untreated de novo AML who are age 60 or older and have at least one of the following adverse prognostic factors: age greater or equal to 70, ECOG performance status equal to 2, unfavorable cytogenetics or organ dysfunction. The primary endpoint of the trial is the overall complete response rate measured as either complete remission (CR) or CRp, a complete response with incomplete platelet recovery. Secondary endpoints are progression-free survival, leukemia-free survival, overall survival and the toxicity of Cloretazine(R) (VNP40101M) in this patient population.

Patients receive induction therapy of 600 mg/m2 of Cloretazine(R) (VNP40101M) in a sixty-minute infusion. Second induction is permitted between days 35 and 60 in patients with bone marrow improvement but residual disease. Patients who respond can receive consolidation therapy with a continuous infusion of 400 mg/m2 of cytar
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Leading events organizer UBM Live announces that ... year to São Paulo, Brazil from ... event will co-locate with Food Ingredients South America (FiSA), creating ... for the pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... are now exploring the South America ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... 19, 2007 - Acorda,Therapeutics (Nasdaq: ACOR) today announced ... Center at the University,of Rochester, will present data ... in multiple sclerosis at the,upcoming American Academy of ... on Wednesday May 2, 2007 at 4:15 pm,Eastern ...
... Full Study Results,to Be Presented at the American ... ,WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) ... of its lead drug,candidate, AGI-1067, did not show ... however, it did achieve a number of,other important ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2AtheroGenics Reports ARISE Trial Results for AGI-1067 2AtheroGenics Reports ARISE Trial Results for AGI-1067 3AtheroGenics Reports ARISE Trial Results for AGI-1067 4
(Date:7/25/2014)... July 26, 2014 2014 Deep ... Confocal Microscope Industry” is a professional and ... Confocal Microscope market. The report provides basic ... Scanning Confocal Microscope definition, classification, application, and ... This research covers international market analysis, including China’s ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... of Dangerous Synthetic Marijuana Increasing (7/3), the state of ... synthetic marijuana, more so even than cocaine. Officials believe the ... safe because it's a “form” of marijuana. However, both doctors ... truth. Going so far as to call it “poison,” doctors ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... As reported by Wood TV 8 in ... Michigan has seen a nearly 500-person increase in heroin related ... was 271 between 1999 and 2002, the toll increased to ... like other states, drug users in Michigan have turned to ... He compared the price of both substances, noting that an ...
Breaking Medicine News(10 mins):Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Distractions Seem More Troublesome With Age 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... executives who have almost 50 years of hospital negotiating experience. Our ... a focus of expertise to help buyers become even more effective. ... all hospital purchases. There is finally help. , ... ...
... rituximab causes considerable kidney injury healing in patients with ... to a study appearing in the November 2008 issue ... Nephrology (CJASN) . The results suggest that this condition, ... percent of cases, can actually be healed in some ...
... Ill., Aug. 5 Healthation CEO Scott Kornhauser,announced ... Services. Collins brings to Healthation more than 20 ... include Vice President of Professional Services of,Aptiv Technology ... will be focused on leading, recruiting, and managing ...
... of Princeton psychology researchers has developed a computer program ... what it is about certain human faces that makes ... they have also found that the program allows them ... or dominant faces possible. , Such work could have ...
... carts from Eagle MHC are designed for maximum cleanability and sterile ... ... -- http://www.eaglegrp.com/ [Steril-Eze® surgical case carts] from Eagle MHC ... product line - which encompasses a wide range of choices in ...
... (NPF) announced it will fund $3.7 million in ... outreach worldwide.,Grants were awarded to institutions in the ... care centers, and 10 outreach,centers. Through centers alone, ... and almost 70,000 patients with movement disorders., ...
Cached Medicine News:Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 3Health News:Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease 2Health News:Whom do we fear or trust? 2Health News:Whom do we fear or trust? 3Health News:New Steril-Eze Surgical Case Carts from Eagle MHC Feature Rugged, Easy-Clean Design 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2
... and Only 16-Electrode Non-Rechargeable ... of RESTORE with the convenience of ... unrivaled RESTOREPRIME. The ultimate non-rechargeable device, ... managing patients with bilateral and complex ...
... a rechargeable neurostimulator equipped with a battery ... a 9-year FDA approved battery life. It ... market. This is helpful to people who ... What makes RESTOREADVANCED and PRIMEADVANCED different from ...
... is an acellular dermal matrix derived from ... AATB-compliant tissue banks utilizing the standards of ... and Food and Drug Administration's (FDA) guidelines. ... and not significantly changed in structure from ...
... a modular external fixation system designed to ... clinical needs. Originally marketed in Europe under ... 20 year history of clinical use in ... principles of the Ilizarov technique begun in ...
Medicine Products: